Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

HAYWARD, Calif., Jan. 12 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that it has completed enrollment in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib (A-002) when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.

"We are pleased with the continued progress of our varespladib cardiovascular program targeting secretory phospholipase A2," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with a unique opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"With the varespladib trial fully enrolled, we look forward to reporting the biomarker results and event trends later this year," said Colin Hislop, M.D., Senior Vice President of Clinical Development at Anthera Pharmaceuticals, Inc. "Based upon the positive results from varespladib's two previous Phase II clinical trials that demonstrated lipid-lowering and anti- inflammatory benefits, we look forward to examining the impact of varespladib on the hyper-inflammatory state presented by ACS patients."

Anthera's FRANCIS trial is based upon direct feedback from FDA via the Special Protocol Assessment procedure. The trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. Anthera plans to enroll between 500-700 patients that will be treated for up to six months. The study is being conducted at sites across North America and Europe. The FRANCIS trial is expected to provide further insight into the prevention of secondary Major
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Ophthalmic drug delivery technologies ... challenging endeavors as the anatomy, physiology and biochemistry ... the foreign substances. Ocular drug delivery technologies provide ... and minimal use of needles; also it enables ... provides specific targeting within the ocular globe. On ...
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... p.m., and do you know where your 16-year-old daughter is? ... homework. You wish. Chances are shes probably taking advantage of ... chat rooms, websites and to instant message her friends, including ... has never met in person. , ,Unfortunately, as most parents ...
... with two research grants coming over the transom almost ... a non-profit subsidiary of the Wisconsin Alumni Research Foundation ... study of human embryonic stem cells. , ,The grant ... Human Embryonic Stem Cell Research come from the National ...
... CHICAGO - Here is a joke my dad told me (actually, he ... guys were walking on a beach and they found a bottle with ... out. "Thanks guys! I was in that bottle for 150 years," the ... for letting me out." , ,So the first guy says: "I ...
Cached Biology Technology:Parental Control - Options Vary for Internet Restrictions 2Parental Control - Options Vary for Internet Restrictions 3Double header for research dollars from Washington 2Women in Midwest IT Have to Fight, Work Harder 2Women in Midwest IT Have to Fight, Work Harder 3
(Date:8/22/2014)... . NAIROBI (22 August ... looming as a major threat to food security across the ... last five years, 1.7 million African farmers in 13 countries ... and helped them double or even triple crop yields. , ... Africa (AGRA) focuses on intensive efforts initiated five years ago ...
(Date:8/22/2014)... and clinical research and technological advances, the fight ... spanning multiple fronts. , Work happening in a ... new and more selective therapies for cancer. Researchers ... enzyme overexpressed in certain cancersand they have tested ... Chemistry professor Christopher Cairo and his team synthesized ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... , July 19, 2013 Research ... of the "Iris Biometrics - Global Strategic Business ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , This report analyzes the ... Thousands. The report provides separate comprehensive analytics for the ...
... 2013 Scientists have identified higher levels of a receptor ... that may serve as a new drug target for the ... in EMBO Molecular Medicine , show that elevated levels ... transfection", are associated with a lower likelihood of survival for ...
... take calcium supplements to lower their phosphorous levels may be ... those who take other non-calcium based treatments, according to a ... The study, published today in the Lancet , calls ... phosphate levels in patients with chronic kidney disease. The researchers ...
Cached Biology News:Iris Biometrics - Global Strategic Business Report 2Calcium linked to increased risk of heart disease and death in patients with kidney disease 2
...
...
... kits are designed to rapidly and ... using our patented APA Technology. APAgene ... an extraordinarily competitive price. All necessary ... The Locator Kit can be used ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
Biology Products: